Ankit Mahadevia - Dec 27, 2021 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
CEO and President, Director
Signature
//s/ Tamara Joseph, Attorney-in-Fact for Ankit Mahadevia
Stock symbol
SPRO
Transactions as of
Dec 27, 2021
Transactions value $
-$69,466
Form type
4
Date filed
12/29/2021, 05:26 PM
Previous filing
Aug 30, 2021
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Options Exercise $47.2K +8K +5.55% $5.90 152K Dec 27, 2021 Direct F1, F2
transaction SPRO Common Stock Sale -$117K -8K -5.26% $14.58* 144K Dec 27, 2021 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRO Stock Option (Right to Buy) Options Exercise $0 -8K -1.62% $0.00 487K Dec 27, 2021 Common Stock 8K $5.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 8,000 shares).
F2 Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 78,219 restricted stock units ("RSUs") held by the Reporting Person. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date.
F3 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.77 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4 All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney